Thursday, October 28, 2021
ADVT 
Life

Malaria drug fails to prevent COVID-19 in a rigorous study

Darpan News Desk The Canadian Press, 03 Jun, 2020 08:46 PM
  • Malaria drug fails to prevent COVID-19 in a rigorous study

A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in health workers and others closely exposed to people with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus. The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

“We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota. “But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March. Hydroxychloroquine has long been used for malaria, lupus and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against their use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware’s study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either placebo pills or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor their doctors knew who who was getting what.

After 14 days in the study, 12% on the drug developed COVID-19 symptoms versus 14% in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There’s basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we’d want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective.

“This fits with everything else we’ve seen so far which suggests that it’s not beneficial," said Dr. Peter Bach, director of a health policy centre at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said. “If it does work, it doesn’t work very well.”

Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there’s still a chance that giving the drug sooner than four days after someone’s exposure to the virus may help prevent illness.

But the study “takes ‘home run’ off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug’s use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

MORE Life ARTICLES

Smelling Your Lover's T-shirt Can Improve Sleep

Smelling Your Lover's T-shirt Can Improve Sleep

Having trouble sleeping? Forget counting sheep. All you may need is your romantic partner's favourite T-shirt wrapped around your pillo

Smelling Your Lover's T-shirt Can Improve Sleep

WATCH: 5 Secrets To A Happy Relationship - DARPAN Asks People At The Guildford Mall

DARPAN speaks to Professor of Psychology at SFU Burnaby, Yuthika Girme about what are the ingredients of a healthy happy relationship.

WATCH: 5 Secrets To A Happy Relationship - DARPAN Asks People At The Guildford Mall

Free entry for kids to Vancouver Aquarium during Family Day Weekend

Vancouver Aquarium is offering FREE admission to kids 12-and-under from Saturday, February 15th to Monday, February 17th inclusive

Free entry for kids to Vancouver Aquarium during Family Day Weekend

Winners of LGBTQ+ January Marie Lapuz Youth Leadership Awards 2019 announced

The January Marie Lapuz Youth Leadership Award was created by Sher Vancouver in 2015 to recognize young leaders who are advocates for the LGBTQ+ community.

Winners of LGBTQ+ January Marie Lapuz Youth Leadership Awards 2019 announced

An evening of cooking, conversations, & coconuts

An intimate crowd of 15 Torontonians transported themselves to India, thanks to the personally-designed recipes by Anjum Anand. 

An evening of cooking, conversations, & coconuts

Standing up to Climate Change

Standing up to Climate Change

Climate change grows more and more serious of an issue by the year, and not enough is done to counteract it.

 

Standing up to Climate Change